

# Serum Uric Acid to Serum Creatinine Ratio and Risk of Stroke Recurrence in Young Adults with Ischemic Stroke

Xiaohong Sun, Jie Lv, Zhenghuan Wu, Jun Shi, Hongwei Huang

Department of Neurology, People's Hospital of Liyang, Changzhou, Jiangsu, 213300, People's Republic of China

Correspondence: Hongwei Huang, Department of Neurology, People's Hospital of Liyang, No. 70 West Jianshe Road, Changzhou, 213300, Jiangsu Province, People's Republic of China, Tel/Fax +86 051968091818, Email hhw2hjyyq@vip.163.com

**Background and Aim:** Serum uric acid to serum creatinine ratio (SUA/SCr) is associated with metabolic and cardiovascular diseases. We aimed to investigate the association between SUA/SCr and stroke recurrence among young adults with ischemic stroke.

**Methods:** A total of 428 young patients with ischemic stroke were included in the present study. SUA/SCr was calculated from the concentration of serum uric acid and creatine (uric acid/creatinine). Cox proportional regression models were performed to evaluate the association between SUA/SCr and stroke recurrence. Kaplan–Meier curves were used to compare recurrence rates in different quantiles of SUA/SCr.

**Results:** During a median follow-up of 3.14 years, 51 (10.7%) patients had stroke recurrence. Multivariable analyses indicated that SUA/SCr was associated with stroke recurrence after being adjusted for potential confounders (quantile four versus quantile one: hazard ratio: 3.420; 95% confidence interval: 1.426–8.200;  $P = 0.006$ ). Kaplan–Meier curves revealed that patients with a high concentration of SUA/SCr had an increased stroke recurrence risk. The time-dependent receiver operating characteristic curve showed that the area under the curve for SUA/SCr was above 0.7 during follow-up. Restricted cubic spline presented an increasing trend for the link between SUA/SCr and stroke recurrence among young adults.

**Conclusion:** SUA/SCr was positively associated with the risk of stroke recurrence among young adults with ischemic stroke. Further prospective studies are warranted to assess the causality between SUA/SCr and the development of stroke recurrence among young adults.

**Keywords:** ischemic stroke, recurrence, young adults, uric acid

## Introduction

Ischemic stroke is a leading cause of disability and mortality worldwide.<sup>1</sup> The incidence of ischemic stroke has been increasing among young adults in recent years.<sup>2</sup> Previous studies reported that approximately 10% to 15% of the patients with ischemic stroke were young adults.<sup>3</sup> With a long life expectancy, ischemic stroke in young adults usually damages the quality of life and causes poor outcomes.<sup>4</sup> Approximately 11% of the patients will experience recurrence after the index stroke within 1 year,<sup>5</sup> which will cause more devastating consequences and increase the risk of mortality, disability, and retirement.<sup>6</sup> Despite the advancement in secondary strategies for ischemic stroke, young patients with ischemic stroke are still at an increased risk of recurrent events.<sup>7</sup> Due to different risk factors and stroke etiologies from older patients, there were limited data regarding the prognosis and prediction factors.<sup>8</sup>

Uric acid, the end product of purine metabolism, is a modifiable risk factor for cardiovascular and renal diseases.<sup>9</sup> Prior studies indicated that uric acid was associated with poor outcomes in patients with ischemic stroke.<sup>10</sup> However, researchers also reported that uric acid was protective in the process of oxidative stress and neuronal metabolism.<sup>11</sup> Depending on the renal clearance, the concentration of uric acid could be influenced by the renal dysfunction.<sup>12</sup> Previous studies often ignored the impact of renal function regarding the role of uric acid.<sup>13</sup> Renal function-normalized uric acid

(serum uric acid to serum creatine ratio [SUA/SCr]) has been suggested to be a superior indicator of uric acid. Recent studies found that SUA/SCr was associated with metabolic and cardiovascular diseases.<sup>14</sup> However, few studies have explored the potential role of SUA/SCr among young patients with ischemic stroke.

Hence, we aimed to investigate the association between SUA/SCr and stroke recurrence in young patients with first-ever ischemic stroke.

## Methods

The data that support the findings of this study are available from the corresponding author on reasonable request.

## Study Population

Consecutive patients with ischemic stroke at People's Hospital of Liyang from January 1, 2013 to June 1, 2015 were retrospectively enrolled. All procedures in this study were performed in accordance with the ethical standards of the 1964 Helsinki declaration and its amendments or comparable ethical standards in People's Hospital of Liyang. Patient's consent was waived due to the retrospective design of the study. Patients' data confidentiality was maintained in People's Hospital of Liyang. This study was approved by the ethics review board of People's Hospital of Liyang.

Patients were included if they 1) were aged between 18 and 49 years,<sup>15</sup> 2) were diagnosed with first-ever ischemic stroke within 14 days, 3) had brain computed tomography or magnetic resonance imaging examinations before admission or during hospitalization, 4) had follow-up records at least 6 months after the index stroke or deceased before then. Patients were excluded if they 1) had missing serum uric acid and creatine values and 2) had a recurrent stroke within 21 days after the index stroke.<sup>16</sup>

## Clinical Data

Demographic, stroke risk factors, laboratory data, and radical images were collected in the study. Stroke etiology was classified according to the trial of ORG 10172 in Acute Stroke Treatment classification criterion.<sup>17</sup> Stroke severity was assessed by the National Institute of Health Stroke Scale score (NIHSS).<sup>18</sup> Smoking status was classified as nonsmokers, former smokers, and current smokers.<sup>19</sup> Social-economic status was collected with face-to-face questionnaires, such as annual family income (1 USD = 6.68 RMB) and educational years. Medication information at discharge was collected. Fasting blood samples were collected in the morning within 24 hours after admission. Estimated glomerular filtration (eGFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration equation. Chronic kidney disease (CKD) was classified according to Kidney Disease Outcomes Quality Initiative guidelines. Serum uric acid and creatine were measured using a Hitachi 7060 automated analyzer (Hitachi Koki Co. Ltd., Hitachinaka City, Japan). SUA/SCr was calculated from the concentration of serum uric acid and creatine (uric acid/creatinine).<sup>20</sup>

## Assessment of the Endpoint

The endpoint of the study was stroke recurrence during follow-up (3 months, 6 months and then annually) after the index stroke. Stroke recurrence was defined as a new deficit or a deterioration of the previous deficit which met the criterion of ischemic or hemorrhagic stroke using clinical evidence, imaginal examinations or other available data during each follow-up.<sup>21</sup>

## Statistical Analysis

Continuous variables presented as mean  $\pm$  SD or median (interquartile range) were compared with *t*-test or Mann–Whitney *U*-test as appropriate. Categorical variables presented as n (%) were compared with Fisher's exact test or  $\chi^2$  test as appropriate. We used the multiple imputation method with chain equations to deal with missing values.

The association between baseline characteristics and stroke recurrence was evaluated with Cox proportional hazard models. The proportional assumption was confirmed with the scaled Schoenfeld residuals. Kaplan–Meier curves were used to compare recurrence rates in different quantiles of SUA/SCr with long-rank tests.<sup>22</sup> Multivariable analyses adjusted for different covariates were used to explore the association between SUA/SCr and stroke recurrence. Model 1 was adjusted for age and sex. Model 2 was further adjusted for blood pressure, hypertension, diabetes mellitus, atrial

fibrillation, dyslipidemia, coronary heart disease, smoking status, drinking, white blood cell, neutrophil counts, lymphocyte counts, C-reactive protein, onset to laboratory data, antiplatelet drugs, anticoagulants, statins, antihypertensive drugs and hypoglycemic agents. Model 3 was adjusted for variables with  $P$  value  $<0.1$  in univariate analyses with the backward selection method. Additionally, we explored the association between uric acid and the risk of stroke recurrence after adjustment for eGFR and performed the subgroup analysis according to the stages of CKD.

The discrimination ability of SUA/SCr for stroke recurrence was assessed with the time-dependent receiver operating characteristic curve adjusted for the variables included in model 3.<sup>23</sup> The shape of the association between SUA/SCr and stroke recurrence was examined with restricted cubic spline with four knots (at 5th, 35th, 65th, and 95th percentiles) adjusted for the variables included in model 3.<sup>24</sup> Besides, we used the net reclassification index (NRI) to evaluate the additional performance after adding SUA/SCr into model 3 using continuous, categorical, and inverse probability weighting methods.<sup>25,26</sup>

All statistical tests were conducted with R statistical software version 4.1.0. (R Foundation, Vienna, Austria) and a two-sided  $P$  value  $<0.05$  was considered to be statistically significant.

## Results

A total of 428 young patients with first-ever ischemic stroke (median age: 44 years; 77.8% male) were included in this study. We excluded 31 patients due to missing values of uric acid and creatinine, and 24 patients without follow-up information or who had recurrent stroke within 21 days after the index stroke ([Supplementary Figure 1](#)). During a median follow-up of 3.14 years, 51 (10.7%) patients had stroke recurrence. Compared with patients without stroke recurrence, patients with stroke recurrence had a higher proportion of hypertension ( $P = 0.043$ ), diabetes mellitus ( $P = 0.001$ ), large-artery atherosclerosis stroke subtype ( $P = 0.016$ ), and hypoglycemic agents ( $P = 0.002$ ), a lower proportion of antiplatelet drugs usage at discharge ( $P = 0.033$ ), a higher concentration of fasting blood glucose ( $P = 0.004$ ), SUA/SCr ( $P = 0.017$ ), and eGFR ( $P = 0.027$ ), and a lower concentration of serum creatinine ( $P = 0.044$ , [Table 1](#)). Patients with a high concentration of SUA/SCr had higher body mass index and eGFR, higher proportions of atrial fibrillation and stains usage at discharge, lower NIHSS scores, and different concentrations of lipid profiles ([Supplementary Table 1](#)).

**Table 1** Baseline Characteristics of Patients with or without Recurrence

Characteristics	Without Recurrence (N = 377)	Recurrence (N = 51)	P value
Age, years	44 [40, 47]	44 [40, 47]	0.856
Male, n (%)	295 (78.2)	38 (74.5)	0.672
BMI (kg/m <sup>2</sup> )	25.0 [23.1, 27.1]	25.4 [23.3, 27.5]	0.425
SBP (mmHg)	142 [130, 159]	145 [138, 160]	0.072
DBP (mmHg)	83 [76, 91]	87 [80, 91]	0.185
Hypertension, n (%)	221 (58.6)	38 (74.5)	0.043
Diabetes mellitus, n (%)	58 (15.4)	18 (35.3)	0.001
Atrial fibrillation, n (%)	9 (2.4)	2 (3.9)	0.858
Dyslipidemia, n (%)	264 (70.0)	40 (78.4)	0.281
Coronary heart disease, n (%)	7 (1.9)	2 (3.9)	0.657
Smoking, n (%)			0.076
Nonsmokers	149 (39.5)	13 (25.5)	
Former smokers	17 (4.5)	1 (2.0)	
Current smokers	211 (56.0)	37 (72.5)	
Drinking, n (%)	113 (30.0)	19 (37.3)	0.371
NIHSS, score	2 [0, 6]	3 [1, 8]	0.101
Onset to laboratory data, days	4.0 [2.0, 8.0]	4.0 [2.5, 8.0]	0.988
Laboratory data			
White blood cell (10 <sup>9</sup> /L)	7.6 [6.1, 9.2]	7.8 [6.2, 9.7]	0.660
Neutrophil counts (10 <sup>9</sup> /L)	4.8 [3.6, 6.5]	5.1 [3.6, 8.0]	0.536

(Continued)

**Table 1** (Continued).

Characteristics	Without Recurrence (N = 377)	Recurrence (N = 51)	P value
Lymphocyte counts ( $10^9/L$ )	1.8 [1.4, 2.2]	1.7 [1.2, 2.2]	0.169
C-reactive protein (mg/L)	2.0 [0.5, 4.7]	1.7 [0.5, 4.7]	0.599
Total cholesterol (mmol/L)	3.8 [3.3, 4.5]	3.9 [3.2, 4.5]	0.997
Triglyceride (mmol/L)	1.4 [1.0, 1.9]	1.4 [1.0, 1.8]	0.930
High density lipoprotein (mmol/L)	1.0 [0.8, 1.2]	1.0 [0.8, 1.2]	0.555
Low density lipoprotein (mmol/L)	2.2 [1.7, 2.9]	2.4 [1.7, 3.0]	0.695
Fasting blood glucose (mmol/L)	4.8 [4.5, 5.4]	5.1 [4.7, 6.6]	0.004
Uric acid ( $\mu\text{mol/L}$ )	306 [247, 371]	308 [256.5, 362]	0.716
Creatine ( $\mu\text{mol/L}$ )	64 [55, 75]	59 [50.5, 72]	0.044
eGFR ( $\text{mL/min/1.73 m}^2$ )	112.1 [104.7, 118.8]	117.1 [106.1, 123.1]	0.027
SUA/SCr	4.7 [3.8, 5.6]	5.2 [4.3, 6.5]	0.017
TOAST, n (%)			0.016
Large-artery atherosclerosis	101 (26.8)	25 (49.0)	
Cardio-embolism	16 (4.2)	3 (5.9)	
Small-vessel disease	74 (19.6)	7 (13.7)	
Stroke of other determined source	40 (10.6)	2 (3.9)	
Stroke of undetermined source	146 (38.7)	14 (27.5)	
Education years, n (%)			0.108
0–6	28 (7.4)	6 (11.8)	
6–9	236 (62.6)	26 (51.0)	
9–12	54 (14.3)	13 (25.5)	
>12	59 (15.6)	6 (11.8)	
Family income, \$, n (%)			0.730
1–1497	5 (1.3)	2 (3.9)	
1497–4492	47 (12.5)	7 (13.7)	
4492–7486	134 (35.5)	18 (35.3)	
7486–14,973	121 (32.1)	15 (29.4)	
>14,973	70 (18.6)	9 (17.6)	
Medication at discharge, n (%)			
Antiplatelet drugs	333 (88.3)	39 (76.5)	0.033
Anticoagulants	41 (10.9)	6 (11.8)	1.000
Stains	364 (96.6)	50 (98.0)	0.888
Antihypertensive drugs	284 (75.3)	40 (78.4)	0.756
Hypoglycemic agents	57 (15.1)	17 (33.3)	0.002

**Abbreviations:** BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimate glomerular filtration rate; NIHSS, National Institute of Health Stroke Scale; SBP, systolic blood pressure; SUA/SCr, serum uric acid/serum creatinine.

Univariate analyses revealed that hypertension (hazard ratio [HR]: 2.050; 95% confidence interval [CI]: 1.091–3.852;  $P = 0.026$ ), diabetes mellitus (HR: 2.860; 95% CI: 1.609–5.085;  $P < 0.001$ ), SUA/SCr (HR: 1.348; 95% CI: 1.130–1.609;  $P = 0.001$ ), smoking status (Current smokers versus nonsmokers: HR: 1.904; 95% CI: 1.012–3.583;  $P = 0.046$ ), stroke etiology (small-vessel occlusion versus large-artery atherosclerosis: HR: 0.403; 95% CI: 0.174–0.932;  $P = 0.034$ ), hypoglycemic agents (HR: 2.691; 95% CI: 1.502–4.821;  $P = 0.001$ ), and antiplatelet drugs at discharge (HR: 0.509; 95% CI: 0.266–0.974;  $P = 0.041$ ) were associated with stroke recurrence among young patients ([Supplementary Table 2](#)). Multivariable analyses indicated that SUA/SCr was associated with stroke recurrence after adjusted for covariates included in model 1 (quantile four versus quantile one: HR: 3.576; 95% CI: 1.501–8.519;  $P = 0.004$ ), model 2 (quantile four versus quantile one: HR: 3.323; 95% CI: 1.258–8.780;  $P = 0.007$ ), and model 3 (quantile four versus quantile one: HR: 3.420; 95% CI: 1.426–8.200;  $P = 0.006$ ; [Table 2](#) and [Supplementary Table 3](#)). Patients with higher quantiles of SUA/SCr had higher risks of stroke recurrence in Kaplan–Meier curves ([Figure 1](#)). The time-dependent receiver

**Table 2** Risk of Recurrence in Young Patients with Ischemic Stroke

SUA/SCr	No. of Events (%)	Model 1	P value	Model 2	P value	Model 3	P value
		HR (95% CI)		HR (95% CI)		HR (95% CI)	
Quantile 1	7 (13.7)	Reference		Reference		Reference	
Quantile 2	15 (29.4)	2.479 (1.009–6.092)	0.048	3.262 (1.240–8.578)	0.017	2.686 (1.086–6.642)	0.032
Quantile 3	9 (17.6)	1.340 (0.498–3.607)	0.562	1.815 (0.616–5.349)	0.280	1.489 (0.550–4.031)	0.433
Quantile 4	20 (39.2)	3.576 (1.501–8.519)	0.004	3.323 (1.258–8.780)	0.007	3.420 (1.426–8.200)	0.006
Per 1 SD increase	51 (100)	1.562 (1.202–2.030)	0.001	1.435 (1.086–1.896)	0.015	1.520 (1.181–1.955)	0.001


**Abbreviations:** CI, confidence interval; HR, hazard ratio; SUA/SCr, serum uric acid/serum creatinine.

operating characteristic curve revealed that the area under the curve for SUA/SCr was greater than 0.7 during the long-term follow-up (Figure 2). The net reclassification index indicated that adding SUA/SCr into model 3 could slightly improve the predictive ability without reaching statistical significance (Supplementary Table 4). Uric acid alone was not significantly associated with stroke recurrence after adjustment for eGFR according to the stages of CKD (Supplementary Table 5). The restricted cubic spline showed an increasing trend for the association between SUA/SCr and stroke recurrence among young adults ( $P$  for non-linearity = 0.663, Figure 3).


## Discussion

In the present study, we found that stroke recurrence occurred in 10.7% of the young adults with ischemic stroke in China, and renal function-normalized uric acid (SUA/SCr) was associated with an increased risk of stroke recurrence. To the best of our knowledge, this was the first study to investigate the relation between SUA/SCr and stroke recurrence in young adults.

The role of uric acid in ischemic stroke remains controversial. Weir et al found that uric acid was associated with poor outcomes and future vascular events in patients with ischemic stroke.<sup>10</sup> Retrospective research suggested that uric acid was related to stroke recurrence in older adults with interaction to inflammatory factors.<sup>27</sup> Packer et al proved that uric acid could increase the production of reactive oxygen species and enhance oxidative stress.<sup>28</sup> However, uric


**Figure 1** Recurrence probability after ischemic stroke stratified by SUA/SCr.

**Abbreviation:** SUA/SCr, serum uric acid/serum creatinine.



**Figure 2** Time-dependent ROC curve for SUA/SCr.

**Abbreviations:** ROC, receiver operating characteristic; AUC, area under the curve; SUA/SCr, serum uric acid/serum creatinine.



**Figure 3** Association between SUA/SCr and risk of stroke recurrence.

**Note:** Hazard ratio was compared with a median SUA/SCr of 4.77 in model 2.

**Abbreviation:** SUA/SCr, serum uric acid/serum creatinine.

acid was a neuroprotective biomarker. Sun et al found that uric acid had antioxidant activities that could scavenge reactive oxygen species and improve the prognosis of ischemic stroke. Wang et al performed a retrospective study and found that a higher concentration of uric acid was associated with better neurological functions in male patients and large-artery atherosclerosis stroke.<sup>29</sup> Chamorro conducted the URICO-ICTUS trial to assess the combined effect of uric acid and alteplase for patients with acute ischemic stroke. They reported that uric acid therapy could prevent early



ischemic stroke progression,<sup>30</sup> and the additional use of uric acid did not increase the proportion of patients with excellent outcomes.<sup>31</sup> Besides, uric acid could be affected by kidney function in individuals with normal kidney function. Gianni et al found that uric acid was associated with kidney function in healthy normotensive individuals.<sup>32</sup> Nishida et al found that uric acid excretion was significantly related to creatinine in both healthy individuals and patients with gout.<sup>33</sup> In the present study, we found that SUA/SCr was associated with stroke recurrence instead of uric acid alone, which might be explained by the controversial role of uric acid and its physiological metabolism.

Uric acid, the end product of purine, is excreted through the kidney. The kidney reabsorbs most uric acid in the proximal tubular cells and balances the synthesized and excreted uric acid in human bodies.<sup>34</sup> The relationship between uric acid and renal function indicated that researchers might combine them to explore their roles in diseases. The renal function-normalized uric acid (SUA/SCr) might reflect the net production of uric acid and is a new biomarker for metabolic and cardiovascular diseases.<sup>35</sup> In the Staged Diabetes Targeting Management Study, researchers found that SUA/SCr was positively correlated to  $\beta$ -cell function and insulin resistance in patients with type 2 diabetes.<sup>20</sup> Kawamoto et al found that SUA/SCr was related to the annual estimated glomerular filtration rate decline rate in diabetic patients.<sup>36</sup> Wang et al performed a nationwide study and reported that SUA/SCr was positively associated with cardiovascular disease and partially mediated by metabolic factors.<sup>14</sup> However, studies regarding SUA/SCr and stroke recurrence among young adults were limited.

In our study, the incidence of stroke recurrence among young adults was similar to previous reports. Putaala et al reported that the recurrence rate was 9.4% for young adults with ischemic stroke.<sup>7</sup> Uric acid is also controversial among young adults. Regarding risk factors for ischemic stroke, Krishnan et al performed a 15-year follow-up study to reveal that hyperuricemia was an independent marker of insulin resistance, prediabetes, and diabetes in young adults.<sup>37</sup> Oikonen et al found that uric acid was associated with markers of subclinical atherosclerosis in young adults.<sup>38</sup> Alternatively, Zhang et al found that elevated uric acid was an independent predictor for good outcomes in young Chinese patients with acute ischemic stroke and supported that uric acid may be neuroprotective in the acute phase of young patients.<sup>39</sup> Our study suggested that renal function-normalized uric acid might be more predictive than uric acid among young adults with stroke recurrence in the long term. SUA/SCr might help identify high-risk patients who might benefit from interventions for metabolic diseases like weight control and healthy diets.<sup>40</sup> Physicians should also pay attention to patients with high SUA/SCr values, while uric acid is normal and employs protective strategies such as serum urate-lowering and renal protection therapies.<sup>41</sup>

Additionally, we found that diabetes mellitus, hypertension, antiplatelet drug usage at discharge, and smoking status were associated with stroke recurrence in young adults. Sarecka-Hujar et al conducted a literature review and found that hypertension and diabetes mellitus were more prevalent in young patients with recurrent stroke.<sup>42</sup> Zhao et al performed a retrospective study among young stroke patients with Moyamoya disease and reported that diabetes was an independent risk factor for recurrent stroke.<sup>43</sup> The Italian Project on Stroke in Young Adults suggested that young patients should take secondary preventative medications at discharge routinely, especially antiplatelet drugs.<sup>44</sup> Cigarette consumption could promote atherosclerosis, arterial vasoconstriction and blood pressure elevation and increases the risk of stroke recurrence.<sup>45</sup>

To the best of our knowledge, few studies have investigated the relationship between SUA/SCr and stroke recurrence among young adults. This innovation was a strength of our research. However, several limitations should be addressed in this study. First, this was a single-center database with limited sample size. Second, due to the retrospective nature, we could not provide time-varying changes in SUA/SCr. Repeated measurements of SUA/SCr might be more informative than baseline SUA/SCr. Third, discontinuation of secondary medications might provide additional information on stroke recurrence. Fourth, we could not interpret the metabolic relationship between uric acid and creatinine and whether uric acid reduction therapy could reduce stroke recurrence risk due to the retrospective nature of this study.

In conclusion, the results of this study found that SUA/SCr was positively associated with the risk of stroke recurrence among young adults with ischemic stroke. Further prospective studies are warranted to assess the causality between SUA/SCr and the development of stroke recurrence among young adults.

## Disclosure

The authors have declared no conflicts of interest with respect to the authorship or publication of this article.

## References

- Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. *Circulation*. 2014;129:e28–e292. doi:10.1161/01.cir.0000441139.02102.80
- Ekker MS, Verhoeven JI, Vaartjes I, van Nieuwenhuizen KM, Klijn CJM, de Leeuw F-E. Stroke incidence in young adults according to age, subtype, sex, and time trends. *Neurology*. 2019;92:e2444–e2454. doi:10.1212/WNL.0000000000007533
- Singhal AB, Biller J, Elkind MS, et al. Recognition and management of stroke in young adults and adolescents. *Neurology*. 2013;81:1089–1097. doi:10.1212/WNL.0b013e3182a4a451
- Béjot Y, Bailly H, Durier J, Giroud M. Epidemiology of stroke in Europe and trends for the 21st century. *Presse Medicale Paris Fr* 1983. 2016;45:e391–e398.
- Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. *Stroke*. 2011;42:1489–1494. doi:10.1161/STROKEAHA.110.602615
- Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Anderson CS. Long-term disability after first-ever stroke and related prognostic factors in the Perth Community Stroke Study, 1989–1990. *Stroke*. 2002;33:1034–1040. doi:10.1161/01.STR.0000012515.66889.24
- Putala J, Haapaniemi E, Metso AJ, et al. Recurrent ischemic events in young adults after first-ever ischemic stroke. *Ann Neurol*. 2010;68:661–671. doi:10.1002/ana.22091
- Boot E, Ekker MS, Putala J, Kittner S, De Leeuw FE, Tuladhar AM. Ischaemic stroke in young adults: a global perspective. *J Neurol Neurosurg Psychiatry*. 2020;91:411–417. doi:10.1136/jnnp-2019-322424
- Li P, Zhang L, Zhang M, Zhou C, Lin N. Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: a mechanism for uric acid-induced endothelial dysfunction. *Int J Mol Med*. 2016;37:989–997. doi:10.3892/ijmm.2016.2491
- Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. *Stroke*. 2003;34:1951–1956. doi:10.1161/01.STR.0000081983.34771.D2
- Okafor ON, Farrington K, Gorog DA. Allopurinol as a therapeutic option in cardiovascular disease. *Pharmacol Ther*. 2017;172:139–150. doi:10.1016/j.pharmthera.2016.12.004
- Bos MJ, Koudstaal PJ, Hofman A, Witteman JCM, Breteler MMB. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. *Stroke*. 2006;37:1503–1507. doi:10.1161/01.STR.0000221716.55088.d4
- Hozawa A, Folsom AR, Ibrahim H, Nieto FJ, Rosamond WD, Shahar E. Serum uric acid and risk of ischemic stroke: the ARIC Study. *Atherosclerosis*. 2006;187:401–407. doi:10.1016/j.atherosclerosis.2005.09.020
- Wang A, Tian X, Wu S, et al. Metabolic factors mediate the association between serum uric acid to serum creatinine ratio and cardiovascular disease. *J. Am. Heart Assoc*. 2021;10:e023054. doi:10.1161/JAHA.121.023054
- Nedeltchev K, der Maur TA, Georgiadis D, et al. Ischaemic stroke in young adults: predictors of outcome and recurrence. *J Neurol Neurosurg Psychiatry*. 2005;76:191–195. doi:10.1136/jnnp.2004.040543
- Hata J, Tanizaki Y, Kiyohara Y, et al. Ten year recurrence after first ever stroke in a Japanese community: the Hisayama study. *J Neurol Neurosurg Psychiatry*. 2005;76:368–372. doi:10.1136/jnnp.2004.038166
- Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. *Stroke*. 1993;24:35–41.
- Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. *Stroke*. 1989;20:864–870. doi:10.1161/01.STR.20.7.864
- Chen J, Li S, Zheng K, et al. Impact of smoking status on stroke recurrence. *J Am Heart Assoc*. 2019;8:e011696. doi:10.1161/JAHA.118.011696
- Li M, Gu L, Yang J, Lou Q. Serum uric acid to creatinine ratio correlates with  $\beta$ -cell function in type 2 diabetes. *Diabetes Metab Res Rev*. 2018;34:e3001. doi:10.1002/dmrr.3001
- Stroke–1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO task force on stroke and other cerebrovascular disorders. *Stroke*. 1989;20:1407–1431. doi:10.1161/01.STR.20.10.1407
- D’Agostino RB, Nam B-H. Evaluation of the performance of survival analysis models: discrimination and calibration measures. In: *Advances in Survival Analysis*. Elsevier. 2003;1–25.
- Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. *Biometrics*. 2000;56(2):337–344. doi:10.1111/j.0006-341X.2000.00337.x
- Durrleman S, Simon R. Flexible regression models with cubic splines. *Stat Med*. 1989;8(5):551–561. doi:10.1002/sim.4780080504
- Pencina MJ, D’Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. *Stat Med*. 2011;30:11–21. doi:10.1002/sim.4085
- Uno H, Tian L, Cai T, Kohane IS, Wei LJ. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. *Stat Med*. 2013;32:2430–2442. doi:10.1002/sim.5647
- Zhu H-Y, Zhao S-Z, Zhang M-L, et al. Elevated serum uric acid increases the risk of ischemic stroke recurrence and its inflammatory mechanism in older adults. *Front Aging Neurosci*. 2022;14:822350. doi:10.3389/fnagi.2022.822350
- Packer M. Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors. *J Card Fail*. 2020;26:977–984. doi:10.1016/j.cardfail.2020.08.015
- Tscharre M, Herman R, Rohla M, et al. Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. *Atherosclerosis*. 2018;270:173–179. doi:10.1016/j.atherosclerosis.2018.02.003
- Amaro S, Laredo C, Renu A, et al. Uric acid therapy prevents early ischemic stroke progression: a tertiary analysis of the URICO-ICTUS trial (Efficacy Study of Combined Treatment With Uric Acid and r-tPA in Acute Ischemic Stroke). *Stroke*. 2016;47:2874–2876. doi:10.1161/STROKEAHA.116.014672



31. Chamorro Á, Amaro S, Castellanos M, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. *Lancet Neurol.* **2014**;13:453–460. doi:10.1016/S1474-4422(14)70054-7
32. Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. *Am J Kidney Dis off J Natl Kidney Found.* **2010**;56:264–272. doi:10.1053/j.ajkd.2010.01.019
33. Nishida Y. Relation between creatinine and uric acid excretion. *Ann Rheum Dis.* **1992**;51:101–102. doi:10.1136/ard.51.1.101
34. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. *Cleve Clin J Med.* **2008**;75(Suppl 5):S13–16. doi:10.3949/ccjm.75.Suppl\_5.S13
35. Kawamoto R, Ninomiya D, Akase T, et al. Serum uric acid to creatinine ratio independently predicts incident metabolic syndrome among community-dwelling persons. *Metab Syndr Relat Disord.* **2019**;17:81–89. doi:10.1089/met.2018.0055
36. Kawamoto R, Ninomiya D, Kikuchi A, et al. Serum uric acid to creatinine ratio is a useful predictor of renal dysfunction among diabetic persons. *Diabetes Metab Syndr.* **2019**;13:1851–1856. doi:10.1016/j.dsx.2019.04.023
37. Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. *Am J Epidemiol.* **2012**;176:108–116. doi:10.1093/aje/kws002
38. Oikonen M, Wendelin-Saarenhovi M, Lyytikäinen L-P, et al. Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in Young Finns study. *Atherosclerosis.* **2012**;223:497–503. doi:10.1016/j.atherosclerosis.2012.05.036
39. Zhang B, Gao C, Yang N. Is elevated SUA associated with a worse outcome in young Chinese patients with acute cerebral ischemic stroke? *BMC Neurol.* **2010**;10:1–6. doi:10.1186/1471-2377-10-82
40. Zhao Y, Sun H, Zhang W, et al. Elevated triglyceride-glucose index predicts risk of incident ischaemic stroke: the Rural Chinese cohort study. *Diabetes Metab.* **2021**;47:101246. doi:10.1016/j.diabet.2021.101246
41. Caimi G, Urso C, Brucculeri S, Amato C, Lo Presti R, Carlisi M. Uric acid and uric acid/creatinine ratio and their correlations with the hemorheological determinants in subjects with subclinical carotid atherosclerosis. *Clin Hemorheol Microcirc.* **2022**;81:47–55. doi:10.3233/CH-211322
42. Sarecka-Hujar B, Kopyta I. Risk factors for recurrent arterial ischemic stroke in children and young adults. *Brain Sci.* **2020**;10:E24. doi:10.3390/brainsci10010024
43. Zhao M, Deng X, Gao F, et al. Ischemic stroke in young adults with moyamoya disease: prognostic factors for stroke recurrence and functional outcome after revascularization. *World Neurosurg.* **2017**;103:161–167. doi:10.1016/j.wneu.2017.03.146
44. Pezzini A, Grassi M, Lodigiani C, et al. Predictors of long-term recurrent vascular events after ischemic stroke at young age: the Italian project on stroke in young adults. *Circulation.* **2014**;129:1668–1676. doi:10.1161/CIRCULATIONAHA.113.005663
45. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. *J Am Coll Cardiol.* **2004**;43:1731–1737. doi:10.1016/j.jacc.2003.12.047

## Neuropsychiatric Disease and Treatment

Dovepress

### Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>